Infection-resistant medical devices

Details Infection-resistant medical devices Infection-resistant medical devices

2008-01-29

2008-01-29

Williams, Catherine S. (Department: 3763)

Surgery

Means for introducing or removing material from body for...

Treating material introduced into or removed from body...

Reexamination Certificate

active

07322965

ABSTRACT:
A method for preventing medical device-associated microorganism infection includes the steps of providing a medical device and incorporating an effective amount of an oxazolidinone compound, such as linezolid, into the medical device.

REFERENCES:
patent: 4723950 (1988-02-01), Lee
patent: 5055455 (1991-10-01), Pier
patent: 5624704 (1997-04-01), Darouichenet et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 6719991 (2004-04-01), Darouiche et al.
patent: 2003/0176848 (2003-09-01), Gibson
patent: 2003/0219461 (2003-11-01), Britten
patent: 2145961 (2000-02-01), None
patent: WO 95/21636 (1995-08-01), None
patent: WO 98/46287 (1998-10-01), None
patent: WO03007870 (2003-01-01), None
patent: WO03061715 (2003-07-01), None
patent: WO03097159 (2003-11-01), None
patent: WO2004014392 (2004-02-01), None
Raad et al “Staphylococcus epidermis: Emerging Resistance and Need for Alternative Agents” (1998) Clinical Infectious Diseases. The University of Chicago 26: 1182-7.
Lizondo et al. “Linezoid” Druges of the Future. (1996) Prous Science Publishers. 21(11): 1116-1123.
Ford et al “In Vivo Activities of U-100592 and U-100766, Novel Oxazolidinone Antimicrobial Agents against Experimental Bacterial Infection” Jun. 1996 vol. 40 Issue 6. pp. 1508-1513.
International Preliminary Examination Report for Application No. PCT/US03/.01710 dated Jan. 28, 2004.
Written Opinion for Application No. PCT/US03/01710, dated Sep. 29, 2003.
International Search Report for Application No. PCT/US03/01710, dated May 19, 2003.
Paradisi, et al., “Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) Antibiotics,” inMedical Clinics of North America, Antibiotic Therapy, Part II, vol. 85, Jan. 2001.
“Linezolid: Oxazolidinone Antibacterial” inDrugs of the Future, vol. 21, 1996.
Raad, et al., “Staphylococcus epidermis: Emerging Resistance and Need for Alternative Agents,”Clinical Infectious Diseases, 1998; 26: 1182-1187.
G. Zerah, et al., “Prevention of Infection Related to Pacemaker Implantation Using Laser Surgery and Prophylactic Antibiotics in a Series of 1184 Patients,”Pacing and Clinical Electrophysiology, vol. 20, Part 2, Sep. 1, 1997.
National Committee for Clinical Laboratory Standards,Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Fifth Edition(2000).
Mittelman, “Recovery and Characterization of Biofilm Bacteria Associated with Medical Devices,” inMethods in Enzymology, vol. 310, Biofilms, 1999; 534-536.
Cramton, et al., “The Intercellular Adhesion (ica) Locus is Present inStaphylococcus aureusand Is Required for Biofilm Formation,”Infect. Immun.1999; 67:5427-5433.
Projan, et al., “The Molecular Basis of Pathogenicity,” inThe Staphylococci in Human Disease, 1997, 55-81.
Rupp, “Infections of Intravascular Catheters and Vascular Devices,” inThe Staphylococci in Human Disease, 1997; 379-399.
Mittelman, “Adhesion to Biomaterials,” inBacterial Adhesion: Molecular and Ecological Diversity, 1996; 89-127.
Costerton, “Introduction to Biofilm,”Int. J. Antimicrob. Agents, 1999; 11:217-221.
Rupp, et al., “Characterization of the Importance of Polysaccharide Intercellular Adhesin/Hemagglutinin ofStaphylococcus epidermidisin the Pathogenesis of Biomaterial-Based Infection in a Mouse Foreign Body Infection Model,”Infect. Immun., 1999; 67(5):2627-2632.
Gristina, “Biomaterial-Centered Infection: Microbial Adhesion Versus Tissue Integration,”Science, 1987; 237:1588-1595.
Bisognano, et al., “Increases Expression of Fibronectin-Binding Proteins by Fluoroquinolone-ResistantStaphylococcus aureusExposed to Subinhibitory Levels of Ciprofloxacin,”Antimicrob. Agents Chemother., 1997; 41(5):906-913.
Rupp, et al., “Characterization ofStaphylococcus epidermidisPolysaccharide Intercellular Adhesin/Hemagglutinin in the Pathogenesis of Intravascular Catheter-Associated Infection in a Rat Model,”Infect. Immun., 1999; 67(5):2656-2659.
Clemett, et al., “Linezolid: New Drug Profile,”Drugs, 2000; 59(4):815-827.
Shinabarger, “Mechanism of Action of the Oxazolidinone Antibacterial Agents,”Expert Opin. Invest. Drug., 1999; 8:1195-1202.
Davenport, et al., “Usefulness of a Test for Slime Production as a Marker for Clinically Significant Infections with Coagulase-Negative Staphyloccoci,”J. Infect. Dis., 1986; 153(2):332-339.
Deighton, et al., “Adherence Measured by Microtiter Assay as a Virulence Marker forStaphylococcus epidermidisInfections,”J. Clin. Microbiol., 1990; 28(11);2442-2447.
Christensen, et al., “Adherence of Coagulase-Negative Staphylococci to Plastic Tissue Culture Plates: A Quantitative Model for the Adherence of Staphylococci to Medical Devices,”J. Clin. Microbiol., 1985; 22(6):996-1006.
Khardori, et al., “Effect of Subinhibitory Concentrations of Clindamycin and Trospectomycin on the Adherence ofStaphylococcus epidermidisin an In Vitro Model of Vascular Catheter Colonization,”J. Infect. Dis., 1991, 164:108-113.
Rachid, et al., “Effect of Subinhibitory Antibiotic Concentrations on Polysaccharide Intercellular Adhesin Expression in Biofilm-FormingStaphylococcus epidermidis,”Antimicrob. Agents Chemother., 2000; 44(12):3357-3363.
Schifferli, et al., “Bacterial Adhesion: Modulation by Antibiotics Which Perturb Protein Synthesis,”Antimicrob. Agents Chemother., 1988; 32(11):1603-1608.
Shibl, “Influence of Subinhibitory Concentrations of Antibiotics on Virulence of Staphylococci,”Rev. Infect. Dis., 1987; 9(4):704-712.
Carsenti-Etesse, et al., “Effects of Subinhibitory Concentrations of Vancomycin and Teicoplanin on Adherence of Staphylococci to Tissue Culture Plates,”Antimicrob. Agents Chemother., 1993; 37(4):921-923.
Rupp, et al., “Effect of Subinhibitory Concentrations of Vancomycin, Cefazolin, Ofloxacin, L-Ofloxacin and D-Ofloxacin on Adherence to Intravascular Catheters and Biofilm Formation byStaphylococcus epidermidis,”J. Antimicrob. Chemother., 1998; 41:155-161.
Schadow, et al., “Characteristics of Adherence to Plastic Tissue Culture Plates of Coagulase-Negative Staphylococci Exposed to Subinhibitory Concentrations of Antimicrobial Agents,”J. Infect. Dis., 1988; 157(1):71-77.
Wilcox et al., “Effects of Carbon Dioxide and Sub-Lethal Levels of Antibiotics on Adherence of Coagulase-Negative Staphylococci to Polystyrene and Silicone Rubber,”J. Antimicrob. Chemother.1991; 27:577-587.
Mermei, L A. et al., Guildelines for the Management fo Intravascular Catheter-Related Infections, Clinical Infectious Deseases, 2001: 32:1249-72.
Cammarata, Sue K et al., Incidence of intravenous catheter-related complications during clinical trials of linezolid, an oxazolidinone., Clinical Infectious Diseases, 31(1), Jul. 2000. 225.
Leach T S et al, Clinical efficacy of linezolid for infections caused by vancomycin-resistant enterococci (VRE) in a compassionate-use program. Clinical Infectious Diseases. vol. 31(1), 224, 2000.
Birmingham M C et al., Treating outpatients (outpts) with significant, resistant Gram-positive infectious with linezolid (LNZ). Clinical Infectious Diseases, vol. 31(1), 224, 2000.
Chien J W et al., Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases vol. 30(1), pp. 146-151, 2000.
McNeil S A et al., Successful treatment of vancomycin-resistantEnterococcus faeciumbacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clinical Infectious Diseases, vol. 30(2) pp. 403-404, 2000.
Smith P F, et al., Clinical outcomes (CO), safety and tolerance of linezolid (LZD) for resistant Gram-positive (G+) infections in patients with neutropenia. Clinical Infectious Diseases, vol. 29(4), p. 960, 1999.
McGahee W, et al., Staphylococcal infections in the

Affiliated with

Also associated with

Rating

Infection-resistant medical devices does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Infection-resistant medical devices, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infection-resistant medical devices will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2801699